Compare Eli Lilly And Co (LLY) vs VF Corp (VFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs VF Corp — how do they compare? Eli Lilly And Co trades at $1,173.02 (market cap $1.04T), while VF Corp trades at $15.16 (market cap $5.71B). The key difference: Eli Lilly And Co is far larger — about 182.1× VF Corp's market cap, and VF Corp pays the higher dividend (2.48%). Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and VF Corp for 65 Days on average.
| LLY | VFC | |
|---|---|---|
Market Cap | $1.04T | $5.71B |
Volume | 3,064,878 | 8,987,330 |
Sector | Health | Consumer Cyclical |
52-Week High | $1.28K | $21.55 |
52-Week Low | $799.57 | $12.62 |
Typical Hold Time | 93 Days | 65 Days |
Enterprise Value | $1.09T | $10.00B |
Dividend Yield | 0.59% | 2.48% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,176.69, down 1.01% on the day, amid a bullish technical outlook and strong fundamental performance. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 consensus. Revenue surged to $65.18B in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing growth prospects.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include elevated valuation multiples and competitive pressures in the pharmaceutical sector. With a consensus price target of $1,350, upside potential exists, but investors should weigh execution risks against the company's innovation pipeline.
VFC trades at $15.00, up 4.31% today, showing recent volatility amid mixed earnings results. The stock maintains a bullish technical signal with strong moving average support, while fundamentals reveal declining revenue from $11.8B in 2022 to $9.5B in 2025 and negative net income of -$189.72M. Analyst consensus leans Hold with a $18.33 price target, representing 22% upside potential. Recent news highlights ongoing challenges with Vans brand performance despite strength in Outdoor segments.
VFC presents a turnaround opportunity with discounted valuation (P/S 0.61) but faces execution risks from brand-specific weaknesses. The company's deleveraging progress and dividend cut signal financial discipline, though sustained revenue growth remains critical for recovery. Near-term catalysts include Q3 2026 earnings and continued Outdoor segment momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About VF Corp
VF designs, produces, and distributes branded apparel and accessories. Its largest apparel categories include action sports, outdoor, and workwear. Its portfolio of about a dozen brands includes Vans, The North Face, Timberland, Supreme, and Dickies. VF markets its products in the Americas, Europe, and Asia-Pacific through wholesale sales to retailers, e-commerce, and branded stores owned by the company and partners. The company has grown through multiple acquisitions and traces its roots to 1899.
Read more on VFC →
